Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
about
Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology GroupA phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.Profile and potential of ixabepilone in the treatment of pancreatic cancerOptimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.The epothilones: new therapeutic agents for castration-resistant prostate cancer.Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCAdvancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review.Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer.Update on rupatadine in the management of allergic disorders.
P2860
Q30433670-3331E696-E831-49E9-B54A-BC034E299A85Q33387547-73A10802-90DC-4C75-8265-2F27E25DD086Q33400047-EA8D6301-080D-48AF-B4A3-B3CA287BD6C7Q33526311-26566BB0-7449-449E-9BC7-8BAB95C927BEQ33933685-A72C9A61-6A26-407D-A28A-243FF33E1C00Q34204598-2B02927D-B811-4818-AA00-AE7499F1C295Q34788890-C6B2D254-310F-43B6-A855-F8C6261CE60BQ35584399-EBAAD832-E550-4870-8345-0A954985A3AAQ35847455-1C614735-FB4D-47BE-A1F1-4CC79F5934AEQ35975007-5338F463-57C9-45F1-8CB5-4497ADA430D2Q35997562-E5252D2E-394A-4B9F-BF59-755B3A29AAB1Q37356274-29BFF113-3B45-49AF-A4F6-9EF8FF501C7EQ38285821-4CE69A02-6CD0-4EAF-A580-0750E29B845B
P2860
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Phase I dose escalation study ...... have failed standard therapy.
@en
Phase I dose escalation study ...... have failed standard therapy.
@nl
type
label
Phase I dose escalation study ...... have failed standard therapy.
@en
Phase I dose escalation study ...... have failed standard therapy.
@nl
prefLabel
Phase I dose escalation study ...... have failed standard therapy.
@en
Phase I dose escalation study ...... have failed standard therapy.
@nl
P2093
P2860
P356
P1476
Phase I dose escalation study ...... have failed standard therapy.
@en
P2093
Ahmad Awada
Chi-Yuan Wu
David Lebwohl
Howard A Burris
Martine J Piccart
Ronald A Peck
Suzanne F Jones
Thierry Gil
P2860
P304
P356
10.2217/THY.09.1
P577
2008-04-29T00:00:00Z